683 Capital Management LLC bought a new stake in shares of Applied Genetic Technologies Corp (NASDAQ:AGTC) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 216,032 shares of the biotechnology company’s stock, valued at approximately $778,000. 683 Capital Management LLC owned approximately 1.19% of Applied Genetic Technologies at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of AGTC. Municipal Employees Retirement System of Michigan grew its stake in Applied Genetic Technologies by 66.7% in the 4th quarter. Municipal Employees Retirement System of Michigan now owns 311,820 shares of the biotechnology company’s stock valued at $1,123,000 after acquiring an additional 124,810 shares during the period. Two Sigma Investments LP grew its stake in Applied Genetic Technologies by 29.9% in the 4th quarter. Two Sigma Investments LP now owns 60,892 shares of the biotechnology company’s stock valued at $219,000 after acquiring an additional 14,011 shares during the period. Renaissance Technologies LLC grew its stake in Applied Genetic Technologies by 32.5% in the 4th quarter. Renaissance Technologies LLC now owns 444,428 shares of the biotechnology company’s stock valued at $1,600,000 after acquiring an additional 109,128 shares during the period. Spark Investment Management LLC grew its stake in Applied Genetic Technologies by 122.1% in the 4th quarter. Spark Investment Management LLC now owns 107,700 shares of the biotechnology company’s stock valued at $387,000 after acquiring an additional 59,200 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in Applied Genetic Technologies by 48.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 394,490 shares of the biotechnology company’s stock valued at $1,558,000 after acquiring an additional 128,049 shares during the period. 45.88% of the stock is owned by hedge funds and other institutional investors.
Shares of AGTC stock opened at $4.15 on Wednesday. Applied Genetic Technologies Corp has a one year low of $3.25 and a one year high of $7.25. The stock has a market cap of $83.28, a price-to-earnings ratio of -6.92 and a beta of 2.18.
Applied Genetic Technologies (NASDAQ:AGTC) last announced its earnings results on Friday, February 9th. The biotechnology company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.20). Applied Genetic Technologies had a negative return on equity of 9.21% and a negative net margin of 33.24%. The business had revenue of $4.85 million for the quarter, compared to analyst estimates of $8.72 million. During the same period last year, the firm earned $0.10 EPS. The company’s revenue for the quarter was down 55.5% compared to the same quarter last year. research analysts anticipate that Applied Genetic Technologies Corp will post -1.3 earnings per share for the current year.
A number of equities research analysts recently issued reports on AGTC shares. Zacks Investment Research cut shares of Applied Genetic Technologies from a “hold” rating to a “sell” rating in a research note on Tuesday, January 9th. ValuEngine cut shares of Applied Genetic Technologies from a “sell” rating to a “strong sell” rating in a research note on Sunday, December 31st. Cantor Fitzgerald reissued a “hold” rating and issued a $9.00 price target on shares of Applied Genetic Technologies in a research note on Wednesday, January 17th. Wedbush reissued an “outperform” rating on shares of Applied Genetic Technologies in a research note on Friday, February 9th. Finally, HC Wainwright set a $8.00 price target on shares of Applied Genetic Technologies and gave the company a “buy” rating in a research note on Friday, February 9th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company. Applied Genetic Technologies currently has an average rating of “Hold” and a consensus price target of $9.00.
COPYRIGHT VIOLATION WARNING: This story was reported by Stock Observer and is the sole property of of Stock Observer. If you are accessing this story on another site, it was stolen and reposted in violation of US & international copyright legislation. The original version of this story can be read at https://www.thestockobserver.com/2018/03/21/683-capital-management-llc-takes-778000-position-in-applied-genetic-technologies-corp-agtc.html.
Applied Genetic Technologies Profile
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. The Company develops gene therapy products designed to manage the lives of patients with severe diseases in ophthalmology. As of March 31, 2016, its product candidates included treatments for X-linked retinoschisis (XLRS), over two forms of achromatopsia (ACHM) and X-linked retinitis pigmentosa (XLRP).
Want to see what other hedge funds are holding AGTC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Applied Genetic Technologies Corp (NASDAQ:AGTC).
Receive News & Ratings for Applied Genetic Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied Genetic Technologies and related companies with MarketBeat.com's FREE daily email newsletter.